 |
PDBsum entry 4fap
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chain A:
E.C.5.2.1.8
- peptidylprolyl isomerase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
[protein]-peptidylproline (omega=180) = [protein]-peptidylproline (omega=0)
|
 |
 |
 |
 |
 |
Peptidylproline (omega=180)
|
=
|
peptidylproline (omega=0)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chain B:
E.C.2.7.11.1
- non-specific serine/threonine protein kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
|
1.
|
L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H+
|
|
2.
|
L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H+
|
|
 |
 |
 |
 |
 |
L-seryl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-seryl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
L-threonyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-threonyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Acta Crystallogr D Biol Crystallogr
55:736-744
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution.
|
|
J.Liang,
J.Choi,
J.Clardy.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The structure of the FKBP12-rapamycin-FRB ternary complex has now been refined
at 2.2 A resolution. The cell-cycle arrest agent rapamycin binds FK506-binding
protein (FKBP12) and the FKBP12-rapamycin binding (FRB) domain of
FKBP12-rapamycin associated protein (FRAP) simultaneously, and the inhibition of
FRAP is responsible for rapamycin's biological activity. The conformation of
rapamycin in the ternary complex is very similar to that observed in the
FKBP12-rapamycin binary complex, with an r.m.s. difference of only 0.30 A.
However, a slight (9 degrees ) rotation repositions the FRB-binding face of
rapamycin in the ternary complex. There are extensive rapamycin-protein
interactions and relatively few interactions between the two protein partners
FKBP12 and FRB, these interactions mainly involving residues in the 40s and 80s
loops of FKBP12 and alpha1 and alpha4 of FRB. The high-resolution refinement has
revealed the crucial role of several buried waters in the formation of the
ternary complex.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1 Chemical structures of (a) FK506 and (b) rapamycin,
showing the regions interacting with FKBP12 and FRB or
calcineurin (effector region).
|
 |
Figure 2.
Figure 2 Stereoviews of (a) the rapamycin-binding pocket of FRB
and (b) the rapamycin-binding pocket of FKBP12. Hydrogen bonds
between rapamycin and FKBP12 are indicated by dashed lines, the
ligand is in bold lines and the protein has light lines and
residue labels.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the IUCr:
Acta Crystallogr D Biol Crystallogr
(1999,
55,
736-744)
copyright 1999.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
Google scholar
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.A.Shertz,
R.J.Bastidas,
W.Li,
J.Heitman,
and
M.E.Cardenas
(2010).
Conservation, duplication, and loss of the Tor signaling pathway in the fungal kingdom.
|
| |
BMC Genomics,
11,
510.
|
 |
|
|
|
|
 |
L.N.Johnson
(2009).
Protein kinase inhibitors: contributions from structure to clinical compounds.
|
| |
Q Rev Biophys,
42,
1.
|
 |
|
|
|
|
 |
N.Jullien,
F.Sampieri,
A.Enjalbert,
and
J.P.Herman
(2003).
Regulation of Cre recombinase by ligand-induced complementation of inactive fragments.
|
| |
Nucleic Acids Res,
31,
e131.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |
|